WO1987006941A1
(en)
|
1986-05-05 |
1987-11-19 |
The General Hospital Corporation |
Insulinotropic hormone
|
US7138486B2
(en)
|
1986-05-05 |
2006-11-21 |
The General Hospital Corporation |
Insulinotropic hormone derivatives and uses thereof
|
US6849708B1
(en)
|
1986-05-05 |
2005-02-01 |
The General Hospital Corporation |
Insulinotropic hormone and uses thereof
|
US5614492A
(en)
*
|
1986-05-05 |
1997-03-25 |
The General Hospital Corporation |
Insulinotropic hormone GLP-1 (7-36) and uses thereof
|
ATE193541T1
(de)
*
|
1989-03-20 |
2000-06-15 |
Gen Hospital Corp |
Insulinotropes hormon
|
EP0512042B1
(de)
*
|
1990-01-24 |
1998-04-08 |
BUCKLEY, Douglas I. |
Glp-1-analoga verwendbar in der diabetesbehandlung
|
US5545618A
(en)
*
|
1990-01-24 |
1996-08-13 |
Buckley; Douglas I. |
GLP-1 analogs useful for diabetes treatment
|
USRE37302E1
(en)
*
|
1992-03-19 |
2001-07-31 |
Novo Nordisk A/S |
Peptide
|
DK36392D0
(da)
*
|
1992-03-19 |
1992-03-19 |
Novo Nordisk As |
Anvendelse af kemisk forbindelse
|
US6284727B1
(en)
*
|
1993-04-07 |
2001-09-04 |
Scios, Inc. |
Prolonged delivery of peptides
|
CA2137206A1
(en)
*
|
1993-12-09 |
1995-06-10 |
John A. Galloway |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5705483A
(en)
*
|
1993-12-09 |
1998-01-06 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptides, compositions and methods
|
US5574008A
(en)
*
|
1994-08-30 |
1996-11-12 |
Eli Lilly And Company |
Biologically active fragments of glucagon-like insulinotropic peptide
|
US5512549A
(en)
*
|
1994-10-18 |
1996-04-30 |
Eli Lilly And Company |
Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
|
ATE234625T1
(de)
*
|
1994-12-23 |
2003-04-15 |
Novo Nordisk As |
Glp-1 zusammensetzungen mit verlängerter wirkdauer
|
US5990077A
(en)
*
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
US5834428A
(en)
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
US6184201B1
(en)
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
US6268343B1
(en)
|
1996-08-30 |
2001-07-31 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
CZ300837B6
(cs)
|
1996-08-30 |
2009-08-26 |
Novo Nordisk A/S |
Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
|
US7235627B2
(en)
|
1996-08-30 |
2007-06-26 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
US6458924B2
(en)
|
1996-08-30 |
2002-10-01 |
Novo Nordisk A/S |
Derivatives of GLP-1 analogs
|
EP1062240B1
(de)
|
1998-02-27 |
2010-04-28 |
Novo Nordisk A/S |
N-terminal veränderte glp-1 abkömmlinge
|
JP2002504518A
(ja)
*
|
1998-02-27 |
2002-02-12 |
ノボ ノルディスク アクティーゼルスカブ |
部分的に構造化されたミセルー様凝集体を形成する、25%を超えるヘリックス−含有率を有するglp−1誘導体
|
ATE466026T1
(de)
|
1998-02-27 |
2010-05-15 |
Novo Nordisk As |
Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
|
WO1999043708A1
(en)
|
1998-02-27 |
1999-09-02 |
Novo Nordisk A/S |
Glp-1 derivatives of glp-1 and exendin with protracted profile of action
|
AU2610699A
(en)
|
1998-02-27 |
1999-09-15 |
Novo Nordisk A/S |
Derivatives of glp-1 analogs
|
EP1932535A3
(de)
|
1998-07-31 |
2008-10-29 |
Novo Nordisk A/S |
Anregung der Beta-Zellbildung
|
JP3702181B2
(ja)
|
1998-12-07 |
2005-10-05 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1の類似体
|
ATE307603T1
(de)
*
|
1998-12-22 |
2005-11-15 |
Lilly Co Eli |
Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
|
SI1140148T1
(sl)
*
|
1998-12-22 |
2006-04-30 |
Lilly Co Eli |
Stabilna formulacija raztopine glukagonu podobnega peptida-1
|
US6927214B1
(en)
|
1999-01-15 |
2005-08-09 |
Novo Nordisk A/S |
Non-peptide GLP-1 agonists
|
WO2000055203A1
(en)
|
1999-03-15 |
2000-09-21 |
Novo Nordisk A/S |
Ion exchange chromatographic separation of glp-1 and related peptides
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
US6451987B1
(en)
|
1999-03-15 |
2002-09-17 |
Novo Nordisk A/S |
Ion exchange chromatography of proteins and peptides
|
US6844321B2
(en)
|
2000-01-31 |
2005-01-18 |
Novo Nordisk A/S |
Crystallization of a GLP-1 analogue
|
ES2253353T3
(es)
|
2000-03-08 |
2006-06-01 |
Novo Nordisk A/S |
Reduccion del colesterol serico.
|
DE60134251D1
(de)
|
2000-09-18 |
2008-07-10 |
Sanos Bioscience As |
Verwendung von glp-2-peptiden
|
ATE416784T1
(de)
|
2000-12-01 |
2008-12-15 |
Takeda Pharmaceutical |
Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
|
WO2002048192A2
(en)
*
|
2000-12-13 |
2002-06-20 |
Eli Lilly And Company |
Amidated glucagon-like peptide-1
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
DE602004023626D1
(de)
|
2003-08-21 |
2009-11-26 |
Novo Nordisk As |
Trennung von polypeptiden mit einer racemisierten aminosäure
|
SI2932981T1
(sl)
|
2003-09-19 |
2021-11-30 |
Novo Nordisk A/S |
Albumin-vezavni derivati GLP-1
|
EP1687019B1
(de)
|
2003-11-20 |
2017-11-22 |
Novo Nordisk A/S |
Für die herstellung und verwendung in injektionsvorrichtungen optimale propylenglykol enhaltende peptidformulierungen
|
JP4865565B2
(ja)
|
2003-12-09 |
2012-02-01 |
ノヴォ ノルディスク アー/エス |
Glp−1アゴニストを用いた食物選択の制御
|
US7897566B2
(en)
|
2003-12-16 |
2011-03-01 |
Ipsen Pharma S.A.S. |
Analogues of GLP-1
|
WO2005058252A2
(en)
|
2003-12-16 |
2005-06-30 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Glp-1 pharmaceutical compositions
|
US20050143303A1
(en)
|
2003-12-26 |
2005-06-30 |
Nastech Pharmaceutical Company Inc. |
Intranasal administration of glucose-regulating peptides
|
EP2316446A1
(de)
|
2004-06-11 |
2011-05-04 |
Novo Nordisk A/S |
Bekämpfung von Arzneimittel-induzierter Fettleibigkeit unter Verwendung von GLP-1-Agonisten
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
SG157423A1
(en)
|
2004-12-02 |
2009-12-29 |
Domantis Ltd |
Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
|
WO2007124461A2
(en)
|
2006-04-20 |
2007-11-01 |
Amgen Inc. |
Glp-1 compounds
|
CA2810839A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
|
EP1852108A1
(de)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Zusammensetzungen von DPP-IV-Inhibitoren
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
US20200155558A1
(en)
|
2018-11-20 |
2020-05-21 |
Boehringer Ingelheim International Gmbh |
Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
|
US9441028B2
(en)
|
2008-12-08 |
2016-09-13 |
Novo Nordisk A/S |
Counter current purification of polypeptides
|
KR20120107080A
(ko)
|
2009-11-27 |
2012-09-28 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
US9168288B2
(en)
|
2010-04-09 |
2015-10-27 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
|
WO2011133948A2
(en)
|
2010-04-22 |
2011-10-27 |
Longevity Biotech, Inc. |
Highly active polypeptides and methods of making and using the same
|
JP6034781B2
(ja)
|
2010-05-05 |
2016-11-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
併用療法
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
UY34347A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de función dual para tratar trastornos metabólicos
|
US20130172244A1
(en)
*
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
WO2013171167A1
(en)
|
2012-05-14 |
2013-11-21 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2014010586A1
(ja)
|
2012-07-10 |
2014-01-16 |
武田薬品工業株式会社 |
注射用製剤
|
EP2968469A4
(de)
|
2013-03-15 |
2016-08-31 |
Longevity Biotech Inc |
Peptide mit nichtnatürlichen aminosäuren und verfahren zur herstellung und verwendung davon
|
US20160235810A1
(en)
|
2013-10-18 |
2016-08-18 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
US9526728B2
(en)
|
2014-02-28 |
2016-12-27 |
Boehringer Ingelheim International Gmbh |
Medical use of a DPP-4 inhibitor
|
MX2018015089A
(es)
|
2016-06-10 |
2019-05-13 |
Boehringer Ingelheim Int |
Combinacion de linagliptina y metformina.
|
KR20200044016A
(ko)
|
2017-08-24 |
2020-04-28 |
노보 노르디스크 에이/에스 |
Glp-1 조성물 및 그 용도
|
CN109929806B
(zh)
|
2017-12-19 |
2020-05-08 |
北京吉源生物科技有限公司 |
一种表达glp1和fgf21的干细胞及其用途
|
BR112022013795A2
(pt)
|
2020-02-18 |
2022-09-13 |
Novo Nordisk As |
Composição farmacêutica líquida, e, kit
|